Unknown

Dataset Information

0

[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.


ABSTRACT: PURPOSE:The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer. PROCEDURES:Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model. RESULTS:High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5?±?1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ?12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered. CONCLUSION:[89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.

SUBMITTER: Laforest R 

PROVIDER: S-EPMC5096950 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

[<sup>89</sup>Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.

Laforest Richard R   Lapi Suzanne E SE   Oyama Reiko R   Bose Ron R   Tabchy Adel A   Marquez-Nostra Bernadette V BV   Burkemper Jennifer J   Wright Brian D BD   Frye Jennifer J   Frye Sarah S   Siegel Barry A BA   Dehdashti Farrokh F  

Molecular imaging and biology 20161201 6


<h4>Purpose</h4>The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [<sup>89</sup>Zr]trastuzumab in patients with HER2-positive breast cancer.<h4>Procedures</h4>Twelve women with HER2-positive breast cancer underwent [<sup>89</sup>Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were creat  ...[more]

Similar Datasets

| S-EPMC5750520 | biostudies-literature
| S-EPMC5955803 | biostudies-literature
| S-EPMC5050126 | biostudies-literature
| S-EPMC4967936 | biostudies-literature
| S-EPMC5647229 | biostudies-literature
| S-EPMC3268553 | biostudies-literature
| S-EPMC5125250 | biostudies-literature
| S-EPMC5608788 | biostudies-literature
| S-EPMC8205906 | biostudies-literature
| S-EPMC4828117 | biostudies-literature